Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-center, Open-label, Fixed-sequence Study in Chinese Healthy Male Adults to Evaluate the Effect of AB-106 on the Pharmacokinetics of Digoxin

NCT05357911 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT05357911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05357911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-center, Open-label, Fixed-sequence Study in Chinese Healthy Male Adults to Evaluate the Effect of AB-106 on the Pharmacokinetics of Digoxin
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2021
Completion date
December 3, 2021
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor